Scandion Oncology Q4 2023 - Striving towards randomised controlled data
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2024-03-01 08:10:00
Redeye comments on Scandion Oncology’s Q4 2023 report, with the company having recently presented its plan to drive SCO-101 towards a randomised controlled phase IIb trial in mCRC. We judge the company’s strategy as prudent, though it will need to address financing while running some CORIST part 3 extension cohorts in 2024e to prepare for phase IIb. We do some housekeeping in our model and leave our estimates and valuation largely unchanged.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/